Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 14/20 | 0.66 |
| ▸ | EGFR | P00533 | 14/20 | 0.66 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | ACP1 | P24666 | 1/20 | 0.46 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.46 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.46 |
| ▸ | SSU72 | Q9NP77 | 1/20 | 0.46 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3979493 | 0.92 | EGFR (0.67) | ERBB2EGFRAURKAGRM4ACP1 | |
| SCHEMBL3977278 | 0.92 | ERBB2 (0.64) | ERBB2EGFRAURKAGRM4ACP1 | |
| SCHEMBL1096310 | 0.79 | ERBB2 (1.00) | ERBB2EGFRAURKAGRM4 | |
| SCHEMBL3973068 | 0.78 | ERBB2 (0.62) | ERBB2EGFRAURKAGRM4ACP1 | |
| SCHEMBL3973368 | 0.75 | ERBB2 (1.00) | ERBB2EGFRAURKAGRM4 | |
| SCHEMBL4084766 | 0.74 | ERBB2 (0.61) | ERBB2EGFRAURKAGRM4 | |
| SCHEMBL3974260 | 0.74 | EGFR (1.00) | ERBB2EGFRAURKA | |
| SCHEMBL1105428 | 0.72 | EGFR (1.00) | ERBB2EGFRAURKA | |
| SCHEMBL11740327 | 0.72 | HDAC6 (0.71) | ERBB2EGFRHDAC6 | |
| SCHEMBL15304787 | 0.72 | ACP1 (0.55) | ERBB2EGFRGRM4ACP1PTPN12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009055299-A1 | SUBSTITUTED PYRIMIDINE-5-CARBOXAMIDE AND 5-CARBOXYLIC ESTER KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | WO | claimed |
| US-20090111810-A1 | SUBSTITUTED PYRIMIDINE-5-CARBOXAMIDE AND 5-CARBOXYLIC ESTER KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | claimed |
| WO-2009055299-A1 | SUBSTITUTED PYRIMIDINE-5-CARBOXAMIDE AND 5-CARBOXYLIC ESTER KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111810-A1 | SUBSTITUTED PYRIMIDINE-5-CARBOXAMIDE AND 5-CARBOXYLIC ESTER KINASE INHIBITORS | MAP3K5, FLT3, MAP3K19 | ERBB2 67/4885EGFR 309/4885AURKA 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.